NASDAQ
2.36USD
+0.03 (+1.29%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
25.3M
P/E
—
EPS
—
Beta
0.25
52W range
1.65-3.07
Day range
2.29–2.36
Open
2.31
Prev close
2.33
Volume
38.1K
Avg volume
34.4K
Dividend
0.00
IPO
2008-09-25
https://www.zacks.com/stock/news/2956062/new-strong-sell-stocks-for-july-20th?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|new_zacks_5_rank_stocks-2956062 · 7/20/2026-1.00
https://www.zacks.com/stock/news/2954439/new-strong-sell-stocks-for-july-16th?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|new_zacks_5_rank_stocks-2954439 · 7/16/2026-1.00
https://seekingalpha.com/article/4904317-aytu-biopharma-inc-aytu-q3-2026-earnings-call-transcript · 5/14/2026+0.00
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aytu-biopharma-to-report-fiscal-2026-third-quarter-operational-and-fi-1161780 · 5/6/2026+0.00
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aytu-biopharma-to-report-fiscal-2026-second-quarter-operational-and-f-1130818 · 1/27/2026
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aytu-biopharma-recaps-investor-day-held-on-january-20-2026-1129218 · 1/20/2026+0.20
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aytu-biopharma-to-host-investor-day-on-january-20-2026-in-new-york-ci-1118762 · 12/18/2025+0.60
https://www.zacks.com/stock/news/2790885/aytu-biopharma-inc-aytu-reports-q1-loss-tops-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2790885 · 11/13/2025-0.40
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aytu-biopharma-to-report-fiscal-2026-first-quarter-operational-and-fi-1094587 · 11/5/2025+0.00
https://www.zacks.com/stock/news/2767415/new-strong-sell-stocks-for-oct-13th?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|new_zacks_5_rank_stocks-2767415 · 10/13/2025-1.00
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aytu-biopharma-to-present-at-upcoming-october-2025-conferences-1085165 · 10/10/2025+0.10
https://seekingalpha.com/article/4825293-aytu-biopharma-inc-aytu-q4-2025-earnings-call-transcript · 9/24/2025+0.00
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
